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Abstract
Sirtuin 2 (SIRT2) is a NAD+-dependent deacetylase that has been associated with neurode-
generation and cancer. SIRT2 is composed of a central catalytic domain, the structure of
which has been solved, and N- and C-terminal extensions that are thought to control SIRT2
function. However structural information of these N- and C-terminal regions is missing.
Here, we provide the first full-length molecular models of SIRT2 in the absence and pres-
ence of NAD+. We also predict the structural alterations associated with phosphorylation of
SIRT2 at S331, a modification that inhibits catalytic activity. Bioinformatics tools and molec-
ular dynamics simulations, complemented by in vitro deacetylation assays, provide a con-
sistent picture based on which the C-terminal region of SIRT2 is suggested to function as
an autoinhibitory region. This has the capacity to partially occlude the NAD+ binding pocket
or stabilize the NAD+ in a non-productive state. Furthermore, our simulations suggest that
the phosphorylation at S331 causes large conformational changes in the C-terminal region
that enhance the autoinhibitory activity, consistent with our previous findings that phosphor-
ylation of S331 by cyclin-dependent kinases inhibits SIRT2 catalytic activity. The molecular
insight into the role of the C-terminal region in controlling SIRT2 function described in this
study may be useful for future design of selective inhibitors targeting SIRT2 for therapeutic
applications.
Introduction
The human NAD+-dependent enzyme Sir2-like protein 2 (SIRT2 hereafter, Fig 1) has been
associated with several age-related diseases, including diabetes, cardiovascular diseases, neuro-
degenerative disorders and cancer [1–7]. Hence, targeting SIRT2 may be of therapeutic
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Fig 1. Structural features of SIRT2. (A) Primary sequences of SIRT2 isoform 1 (SIRT2-iso1) and isoform 2
(SIRT2-iso2) aligned with that of Hst2 from S. cerevisiae (obtained using the BLAST webserver (http://blast.
ncbi.nlm.nih.gov/Blast.cgi)). Identical and structurally similar residues are indicated in red and green,
respectively. Solid lines indicate the N-terminal (NT, blue) and C-terminal (CT, red) regions, and so-called
NAD+ cofactor-binding loop (green). The catalytic center residue H150 (black diamond) and the
phosphorylation sites S331 and S335 (orange diamonds) are shown. (B) X-ray structure of the catalytic core
(CC) domain of human SIRT2 (PDB ID: 1J8F [13]). The CC consists of (i) a Rossmann fold (orange), made of
six β-strands forming a parallel β–sheet and six α-helices, (ii) a small domain made up by a zinc binding
pocket and a hydrophobic pocket, which contains a three-stranded antiparallel β-sheet (yellow), an α-helix
(yellow) and a zinc ion (light blue) coordinated by four cysteine residues (C195, C200, C221 and C224
(yellow sticks)), and four α-helices forming a hydrophobic pocket (purple), and (iii) four connecting loops
(green). NAD+ is absent in the crystal structure. It has been included here by superposing the CC of SIRT2
with that of Sir2-Af1 [14], for which a structure with NAD+ is available (NAD+ is in magenta). N and C indicate
the N-terminal and C-terminal ends of the CC, respectively. (C) Structural comparison of the CC domain
obtained from X-ray structure determinations and of the modeled SIRT2/NAD+ complex, the modeled SIRT2
and the modeled SIRT2-pS331. The CC crystal structure and our models are colored in gray and green,
respectively. The NT and CT are colored in blue and pink, respectively. The NAD+ cofactor in the CC of the
modeled SIRT2/NAD+ is represented by orange sticks. The S331/pS331 residues in the CT are represented
by pink sticks.
doi:10.1371/journal.pone.0139095.g001
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relevance. SIRT2 is expressed as two functionally similar isoforms (isoform 1 and 2). Isoform 2
(352 amino acids) lacks the first 37 N-terminal amino acids compared to isoform 1. Both iso-
forms have the same in vitro and in vivo deacetylation activity [8], i.e. SIRT2 deacetylates lysine
residues in a variety of target proteins, thus antagonizing acetyltransferases [9,10]. In the cur-
rent study, we focus on isoform 2 of SIRT2, which is the isoform highly expressed in the mye-
lin-enriched fractions of adult mouse brains and in the cytoplasm of murine cerebellar granule
cells [1,2]. Inhibitors of the catalytic activity of SIRT2 have been shown to interfere with α-
synuclein toxicity [4], which is associated with neurodegeneration in Parkinson’s disease, and
with tumorigenesis [7]. However these inhibitors are non-selective as they bind also to other
members of the sirtuin family [4,11,12].
Previously, we found that cyclin-dependent kinase 2 (CDK2) and CDK5 can phosphorylate
SIRT2 at serine (S) 331 of isoform 2 (corresponds to S368 in isoform 1). This serine residue is
located within the naturally disordered C-terminal region (CT, residues 320–352 in isoform 2).
This phosphorylation inhibits the enzymatic activity of SIRT2 both in vitro and in cells [15].
Gain- and loss-of-function studies revealed that SIRT2 interferes with neurite outgrowth in
postmitotic hippocampal neurons, which is antagonized by CDK-dependent phosphorylation
[15]. In agreement with our findings defining S331 as phosphorylation site, the corresponding
residue S368 in SIRT2 isoform 1 was identified as a target of CDK1 [8]. SIRT2 overexpression
delays cell proliferation, which is dependent on S368 phosphorylation [8]. Together these find-
ings suggest that phosphorylation of the CT affects SIRT2 activity and hence this naturally dis-
ordered region might function as a regulatory domain. In an effort to evaluate whether this is
indeed the case, we have used bioinformatics tools and molecular dynamics (MD) simulations
to provide molecular models of the full-length protein, with and without the NAD+ cofactor
(SIRT2 and SIRT2/NAD+, respectively, hereafter), as well as with a phosphorylated S331 with-
out NAD+ (SIRT2-pS331 hereafter). The predictions are based on the structured catalytic core
(CC, residues 26–319 in isoform 2) deduced from the crystal structure [13]. The calculations
are complemented by enzymatic essays. Our in silico and in vitro approaches provide a consis-
tent picture based on which we suggest that the CT functions as an autoinhibitory region by
partially occluding the NAD+ binding site in SIRT2 or stabilizing the NAD+ in a non-produc-
tive state in SIRT2/NAD+. This occlusion is increased by phosphorylation at S331.
Materials and Methods
Computational chemistry
Modeling of SIRT2/NAD+. SIRT2 contains the CC domain (Fig 1B), for which structural
information is available (PDB ID: 1J8F [13]) and two unstructured regions, the N-terminal
(NT) region and the CT. The CC structure includes a zinc ion, coordinated by four cysteine
residues (C195, C200, C221 and C224) (Fig 1B), but lacks the NAD+ cofactor [13], which is
present in the CC and necessary for the catalytic activity of sirtuins [14,16–19]. The CC shares
the same domain architecture [13] and 26% sequence identity with Sir2-Af1 from A. fulgidus
(PDB ID: 1ICI [14]). Hence, we have obtained an educated guess of the location of the NAD+
cofactor by superimposing the two structures. Next, we constructed structural models of the
NT and CT regions by (i) homology modeling and (ii) ab initiomodeling. (i) Because the
BLAST webserver (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was not able to find suitable tem-
plates for NT and CT, we split these regions into fragments, as described previously [20]. We
identified 26 templates, 13 for NT and 13 for CT, from the BLAST webserver with sequence
identities with the targets ranging from 48% to 100% (Table 1). 200 models of the full-length
SIRT2 isoform 2 were then generated using the MODELLER 9v9 package [21]. (ii) Ab initio
modeling [22], using the Robetta webserver [23], resulted in five full-length SIRT2 models. 172
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models out of 200 generated from homology modeling and all 5 models from ab initiomodel-
ing turned out to have 90% or more residues in the most favored regions of Ramachandran
plots [24]. For this analysis, the Procheck program [25] was used. Six different starting models
(Models 1–6 in Fig 2), representing 86% of the 200 homology models, were identified by a clus-
ter analysis [26]. One ab initiomodel (Model 7 in Fig 2) was selected among the five obtained.
This shows the lowest difference (in terms of secondary structure and root-mean-square devia-
tions (RMSD)) compared with the SIRT2 CC crystal structure [13].
MD simulations of SIRT2/NAD+. Each of the seven selected full-length SIRT2/NAD+
models, obtained from homology and ab initiomodeling was inserted into a cuboid with edge
lengths of 91 Å, 112 Å and 98 Å containing ~31,000 water molecules and six Na+ ions. We
have determined the protonation states of the seven histidines in SIRT2 (H74, H90, H112,
H150, H157, H165 and H312) by combining visual inspection for predicting possible interac-
tions (hydrogen bond patterns or salt bridges) and by using two servers (WHAT IF [53] and H
++ [54]) evaluating the local effects of the flanking amino acids on histidines’ pKa. We have
additionally run short MD simulations (10 ns for each protonation state, with the same compu-
tational setup described below) on one of the seven models to evaluate the effect of the different
protonation states on the SIRT2 structure. We have chosen the configuration with the lowest
Table 1. Templates of the N-terminal (NT) and C-terminal (CT) regions for SIRT2 homology models.
Segment ID PDB ID Template sequence Target sequence Identity (%) Ref.
NT 1 2CX6 D16-D36 D2–D23 55 [27]
2 2OVJ D424-L434 D2–D23 48 [28]
3 3PSE M1–L7 M1–L5 86 [29]
4 2FCG D26-L31 D2–L7 100 [30]
5 2HEK F295-E304 F8–D23 50 [31]
6 3PCO R195-T201 R5–T11 57 [32]
7 1VE2 K169-E174 K18-D23 70 [33]
8 2WSP Q337-L342 Q17-L22 100 [34]
9 3DJA L179-G190 L4–R20 58 [35]
10 1U7J M1–R5 M1–R5 80 [36]
11 1PWX L211-E216 L14-E19 83 [37]
12 3FMC T239-R347 T11-R20 80 [38]
13 1G0D G445-R450 G15-R20 100 [39]
CT 14 3HJT Q60-I65 Q318-V323 83 [40]
15 1V8H P65-P73 P324-P332 78 [41]
16 2DFX P58-P63 P332-P337 83 [42]
17 1XG2 P105-A110 P338-A343 83 [43]
18 1U3O R58-Q66 R344-Q352 78 [44]
19 2CUI G44-T50 G322-T328 86 [45]
20 1YPZ K119-K125 K334-K340 86 [46]
21 2X1L G373-P379 G320-P326 71 [47]
22 1YU3 S216-S222 S329-S335 100 [48]
23 1YQ2 S789-A800 S319-A330 67 [49]
24 3RQR A2913-Q2924 A339-Q352 57 [50]
25 1WQL Q412-N419 Q318-N325 88 [51]
26 1J3L A113-K120 A330-K340 64 [52]
The PDB ID, template sequence, target sequence, template-target identity and reference are given.
doi:10.1371/journal.pone.0139095.t001
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RMSD (Table 2) in respect to the SIRT2 crystal structure for following productive MD simula-
tions, i.e. H74 (Nε), H90 (Nε), H112 (Nδ), H150 (Nε), H157 (Nε), H165 (Nε and Nδ) and
H312 (Nδ)).
Overall, the systems were neutral and underwent MD simulations using the GROMACS 4.5.5
code [55]. The all-atom AMBER ff99SB-ILDN force field [56–59] was used for the protein, Na+
and NAD+. The bonded plus electrostatic model and corresponding zinc AMBER force field
(ZAFF) parameters (tetrahedral four cysteine zinc-bonding configuration [60]) were used for the
zinc and its four cysteine ligands. The van der Waals parameters for the zinc ion were taken from
AMBER ff99SB-ILDN force field [61]. The TIP3P force field [62] was used for the water mole-
cules. All bond lengths were constrained by LINCS algorithm [63]. Periodic boundary conditions
Fig 2. Structural models of the lowest interaction energy docking structure of SIRT2 in complex with
cCDK2 in the largest cluster. The structures of Models 1–6 were initially generated by homology modeling,
while Model 7 was generated by ab initiomodeling (see Materials and Methods for details). The cartoon
representations of CDK2, cyclin A, and SIRT2 are colored in blue, orange, and green, respectively. The CT of
SIRT2 is colored in pink.
doi:10.1371/journal.pone.0139095.g002
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were applied. Electrostatic interactions were calculated using the Particle Mesh-Ewald (PME)
method [64], and van der Waals and Coulomb interactions were truncated at 10 Å.
The systems underwent 1,000 steps of steepest-descent energy minimization with 1,000
kJmol−1Å−2 harmonic position restraints on the protein, followed by 2,500 steps of steepest-
descent and 2,500 steps of conjugate-gradient minimization without restraints. The systems
were then gradually heated from 0 K up to 302 K in 20 steps of 2 ns. After that, equilibration
was performed. Finally, 150 ns long productive MD simulations were carried out for each sys-
tem in the NPT ensemble (constant temperature at 302 K, constant pressure at 1 bar and 2 fs
time step by coupling the systems with a Nosé-Hoover thermostat [65,66] and an Andersen-
Parrinello-Rahman barostat [67]). The most representative structure for each SIRT2/NAD+
model was identified by the cluster analysis [55] over the equilibrated trajectories, ranging
from 30 ns to 120 ns.
Selection of the best full-length SIRT2/NAD+ model. In order to screen across the seven
full-length SIRT2/NAD+ models, each of them was docked onto one of SIRT2's known cellular
Table 2. Average RMSD values of backbone atoms of the CC of SIRT2 in a total of 240 ns MD simulations by using various histidine protonation
states, relative to those in the X-ray structure.
Histidine Protonation state
a b c d e f g h
H74 HIE HIE HIE HIE HIE HIE HIE HIE
H90 HIE HIE HIE HIE HIE HIE HIE HIE
H112 HIP HIP HIP HIP HIP HIP HID HID
H150 HID HID HIE HIE HIP HIP HID HID
H157 HIP HIE HIP HIE HIP HIE HIP HIE
H165 HIP HIP HIP HIP HIP HIP HIP HIP
H312 HID HID HID HID HID HID HID HID
RMSD (Å) 2.4±0.3 2.3±0.3 3.0±0.8 2.1±0.3 2.3±0.3 2.2±0.3 2.6±0.2 2.7±0.5
i j k l m n o p
H74 HIE HIE HIE HIE HIE HIE HIE HIE
H90 HIE HIE HIE HIE HIE HIE HIE HIE
H112 HID HID HID HID HIP HIP HIP HIP
H150 HIE HIE HIP HIP HID HID HIE HIE
H157 HIP HIE HIP HIE HIP HIE HIP HIE
H165 HIP HIP HIP HIP HIP HIP HIP HIP
H312 HID HID HID HID HIP HIP HIP HIP
RMSD (Å) 2.9±0.4 2.0±0.4 2.4±0.3 2.2±0.4 2.3±0.3 2.4±0.4 2.1±0.3 2.4±0.4
q r s t u v w x
H74 HIE HIE HIE HIE HIE HIE HIE HIE
H90 HIE HIE HIE HIE HIE HIE HIE HIE
H112 HIP HIP HID HID HID HID HID HID
H150 HIP HIP HID HID HIE HIE HIP HIP
H157 HIP HIE HIP HIE HIP HIE HIP HIE
H165 HIP HIP HIP HIP HIP HIP HIP HIP
H312 HIP HIP HIP HIP HIP HIP HIP HIP
RMSD (Å) 2.7±0.4 2.2±0.3 2.7±0.6 2.6±0.4 2.2±0.4 2.1±0.3 2.6±0.4 2.2±0.4
The three possible protonation states of histidine are represented by HID (Nδ nitrogen atom protonated), HIE (Nε nitrogen atom protonated) and HIP (both
Nδ and Nε nitrogen atoms protonated). The possible combinations (a-x) are 24. Standard deviations (SD) of RMSD are also reported. The chosen
configuration for MD simulations is state j with the lowest RMSD value compared with others.
doi:10.1371/journal.pone.0139095.t002
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partners [15], the cyclin A/CDK2 complex [15]. Cyclin A/CDK2 (cCDK2) uses its cofactor
ATP to phosphorylate serine or threonine residues of its substrates (the so-called ‘P’ site) fol-
lowed by a proline, highly conserved across nearly all substrates (at the P+1 site), and a basic
residue at the P+3 site [68–70]. Structural information has been provided by the complex
between CDK2 and cyclin A bound to the HHASPRK peptide (the underlined residues are
those recognized by the enzyme) [70].
Two models of cCDK2 were constructed (A and B hereafter). A is based on the X-ray struc-
ture of human CDK2 in complex with cyclin A and the HHASPRK peptide (PDB ID: 1QMZ
[70]). This contains one Mg(II) ion bound to a water molecule, the ATP cofactor, and N132 and
D145 of CDK2. B contains twoMg(II) ions and this species might be present in vivo [71]. The
positions of the secondMg(II) ion and water molecules in model B was determined by superim-
posing the kinase domains of CDK2 (residues 5–209) with the ones of and protein kinase A
(PKA) (PDB ID: 1ATP [72]) PKA (residues 44–245) using PyMOL (Molecular Graphics Sys-
tem, Version 1.3, Schrödinger LLC). The latter kinase shares 32% of sequence identity with
CDK2, and its X-ray structure includes two metal ions and coordinated water molecules [72].
A and B were docked onto the HHASPRK peptide (used for protocol validation) and
SIRT2. In the docking calculations, we considered only non-hydrogen atoms and imposed
restraints between substrate's P site residue and ATP, because the contact between ATP and
the P site residue is the prerequisite for the phosphoryl group transfer reaction [73], and
between substrate's basic residue at the P+3 site and CDK2's pT160 and cyclin A’s I270,
because these contacts are crucial for substrate specificity, as indicated by the crystal structure
of cCDK2•HHASPRK [70]. Distance restraints were applied on Mg(II) ions and their ligands
to preserve the coordination structure using the HADDOCK program [74,75]. Rigid body
docking, semi-flexible simulated annealing and water MD refinement were carried out.
In all docking calculations, adducts with A turned out to feature better HADDOCK scorings
[74,75], number of best-scoring structures, and distance between ATP and the serine at the P
site, than those of B (data not shown). Therefore the adducts with A are shown here. Our dock-
ing calculations further indicate that only one of the seven full-length SIRT2/NAD+ models
could reproduce the conserved interaction patterns between cyclin A/CDK2 and its substrates
as observed in crystal structure [70] (Model 7 in Fig 2). This model was used also to predict the
structure of the full-length apo-SIRT2 model.
Modeling and MD simulations of full-length SIRT2 and SIRT2-pS331. The NAD+
cofactor was manually removed from the SIRT2/NAD+ model determined in previous steps,
and then 150 ns long MD simulations were performed in a cuboid with edge lengths of 93 Å,
101 Å and 100 Å containing ~30,000 water molecules and five Na+ ions with the same compu-
tational set-up as described above. The most representative structure from the equilibrated tra-
jectories (80–150 ns) was identified by the cluster analysis [55]. The most representative
structure of SIRT2 was further used to predict the structure of the SIRT2-pS331 model. 500 ns
long MD simulations were performed in a cuboid with edge lengths of 85 Å, 106 Å and 95 Å
containing ~25,000 water molecules and seven Na+ ions with the same computational set-up as
described above. The most representative structure from the equilibrated trajectories (200–500
ns) was identified by the cluster analysis [55].
Computational analysis. To assess the convergence of each simulated trajectory, we per-
formed the Hess’s analysis [76]. Hydrogen bonds were defined to be present if the distance
between the acceptor and donor atoms is below 3.5 Å and the angle among the hydrogen-
donor-acceptor atoms are below 30 degree. Structural analysis was carried out using the tools
implemented in GROMACS 4.5.5 code [55]. All figures for the visualization of structures were
drawn using PyMOL (Molecular Graphics System, Version 1.3, Schrödinger LLC).
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Plasmids and recombinant proteins
Recombinant proteins were produced in E. coli BL21(DE)pLysS as GST fusion proteins using
the constructs pGEX-SIRT2 (isoform 2) and pGEX-SIRT2-ΔCT (lacking the terminal 32
amino acids). Transformed bacteria were grown to an OD of 0.5–0.7 and protein expression
was induced with 1 mM IPTG at 21°C for 16 h. Bacterial pellets were lysed in buffer containing
20 mM Tris-HCl, pH 8.0, 150 mMNaCl, 1 mM EDTA, 5 mM DTT, 1 mM Pefabloc SC, and
14 μg/ml Aprotinin, sonicated, and centrifuged at 10.000xg at 4°C for 30 min. GST-fusion pro-
teins were separated from the cell lysate on glutathione-agarose (Sigma-Aldrich). The column
was washed in 100 mM Tris-HCl pH 8.0 and 120 mMNaCl, and eluted in 100 mM Tris-HCl,
pH 8.0, 120 mMNaCl, and 20 mM Glutathione. The purified proteins were analyzed on
SDS-PAGE and Coomassie Blue staining.
Deacetylation assays
For deacetylation assays 0.5 μg porcine tubulin (Cytoskeleton Inc.) was incubated in 50 mM
Tris-HCl, pH 8.0, 10% (v/v) Glycerol, 1 mMDTT, 0.1 mM EDTA containing ProteoBlock pro-
tease inhibitor cocktail (Fermentas) with 1 μg of GST or GST fusion proteins. Tubulin (B-5-1-
2, Abcam) and acetylated tubulin (K40ac antibody 6-11B-1, Sigma-Aldrich) were detected on
Western Blots as described before [15]. Moreover we employed the SIRT2 activity assay kit
(ab156066, Abcam, Cambridge, UK) according to the manufacturer’s protocol using GST-
tagged fusion proteins (0.5 μg/assay).
Results and Discussion
The two major SIRT2 isoforms 1 and 2 with 389 and 352 amino acids, respectively, can be
divided into three parts, i.e. the catalytic core domain (CC) and N-terminal (NT) and C-termi-
nal (CT) regions, which flank the CC (Fig 1A). The overall structure of the CC is conserved
across all sirtuin members [18]. It contains a large, structurally homologous Rossmann fold
(the so-called large domain [13]), a small, structurally diverse domain (the so-called small
domain [13]) made up by a zinc binding pocket and a hydrophobic pocket, and four loops con-
necting the two domains (Fig 1B). In contrast the NT and CT show divergence in length and
sequence among sirtuins [77,78]. They are disordered and are presumed to be highly flexible
[18]. In the isoform 2 of SIRT2, modeled in this work, NT and CT are composed of amino
acids 1–25 and 320–352, respectively.
In the following, we will first describe our models of full-length SIRT2 with and without
NAD+ showing how the presence of the CT tail may affect the CC of the protein. Then we dis-
cuss the model of SIRT2 in the presence of pS331 modification. Specifically we show how phos-
phorylation of the CT might interfere with SIRT2 function by modifying the interaction of the
CT with the NAD+ binding site.
Models of full-length wild-type SIRT2
Full-length models of wild-type SIRT2 with and without NAD+ (SIRT2 and SIRT2/NAD+,
respectively) were obtained by combining bioinformatics, modeling techniques and MD simu-
lations. The stability, sampling and convergence of our MD simulations were established by
calculating the backbone RMSD and by performing principal component (PC) analysis. The
RMSD values (S1 and S2A Figs) for backbone atoms of the CC in SIRT2 and SIRT2/NAD+
oscillate around 2 Å compared to the X-ray structure [13]. The NT and CT regions, as
expected, have much larger RMSD. The RMSD values of NT and CT reach a plateau after
around 130 ns and 80 ns in the SIRT2/NAD+ and SIRT2 MD simulations, respectively (S1 and
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S2A Figs). The sampling and convergence of our MD simulations were further checked by the
so-called Hess analysis [76]. In this analysis, the trajectories’ projections on the top essential
dynamical spaces obtained from a standard covariance analysis are considered. These projec-
tions are next compared with those expected for a random reference. The observed negligible
overlap (i.e. cosine content close to 0) that we found for our systems (cosine contents was
0.022, 0.002 and 0.131 for the first three PCs in SIRT2/NAD+, and 0.037, 0.036, and 0.116 for
the first three PCs in SIRT2) confirms a posteriori an adequate sampling of our systems around
the equilibrium position. In the following, we will describe the structural features of our models
for each domain.
The modeled structures show a conserved CC domain highly similar to the X-ray structure
[13] (RMSD values are 2.2±0.2 Å and 2.6±0.2 Å for SIRT2/NAD+ and SIRT2, respectively), a
structurally variable and partially disordered NT, while the presence of a short helical region is
predicted for CT (Fig 1C).
The NT region. The NT extension is located below the large domain of CC in both the
SIRT2/NAD+ and the SIRT2 models, far away from the active site (Fig 1C). This suggests that
the NT does neither influence NAD+ nor substrate binding directly. This is consistent with the
observation that the NT has no effect on the in vitro deacetylase activity of SIRT2 [13]. How-
ever, indirect effects on SIRT2 activity cannot be excluded, e.g. by modulating protein-protein
interactions involved in substrate recognition and in subcellular targeting of the enzyme.
The CC domain. Some of the reported X-ray structures of CC domain of sirtuins host the
NAD+ cofactor required for enzymatic activity [14,16–19]. The NAD+ binding pocket is
located across the Rossmann fold and the hydrophobic pocket (Fig 3A–3C). The NAD+ bind-
ing pocket can be divided into three regions (A, B and C sites) [14]: site A, where the adenine
ribose moiety of NAD+ is bound; site B, where the nicotinamide ribose of NAD+ is bound; and
site C, where the nicotinamide moiety of NAD+ is bound. The location of nicotinamide charac-
terizes a productive or a non-productive state for activating NAD+ [16–18] (Fig 3D). In the for-
mer, the nicotinamide ribose is hydrogen bonded with the acetyl-lysine carbonyl oxygen of the
substrate, which would allow the nucleophilic attack on the nicotinamide ribose for the deace-
tylation catalysis [16–18]. In the latter NAD+ is not properly positioned in site C (Fig 3A)
[14,16,19]. As a result, the nicotinamide moiety of NAD+ fails to interact with key residues
required for catalysis and the complex is not productive.
Both full-length proteins with and without NAD+ are, not unexpectedly, architecturally
similar to the previously reported CC crystal structure (Fig 1C). However, the insertion loop
consisting of L21-α12-L22 (residues 250–280) along with the α11 helix (residues 230–236), and
the cofactor binding loop L4-α3-L5 (residues 55–80, one of the most conserved regions of sir-
tuins [79–82]), rearrange considerably in the presence of the CT because of multiple interac-
tions (Fig 4A). This is of special importance, as they may play a role in NAD+ binding and
substrate recognition [13]. In particular, the insertion loop has been suggested to be important
for substrate selection [13,83]. Thus the CT is likely to contribute, indirectly, to NAD+ binding
and substrate specificity.
In our SIRT2/NAD+ model, NAD+ is bound in a non-productive state (Fig 3A). It binds to
a large groove between the Rossmann fold and the hydrophobic pocket of the smaller domain,
similar to the previously reported structures of sirtuins/NAD+ [14,16–19]. In this conformation
the nicotinamide moiety of NAD+ forms hydrophobic contacts with Q130, H150 and V229
around the active site (Fig 3A). Such weak interactions between nicotinamide and SIRT2 imply
a larger conformational flexibility of nicotinamide in the substrate-free SIRT2, consistent with
the variability of the nicotinamide binding position observed in previously solved crystal struc-
tures [14,16,19]. Such flexibility may ease the passing of NAD+ from the non-productive to the
productive state, accompanied with the rotation of the nicotinamide (shift from hydrophobic
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pocket to interacting with site C) and nicotinamide ribose (bound to site B) of NAD+ in the
presence of substrates [84]. The nicotinamide ribose in site B forms two hydrogen bonds with
CC residues, R60 with the oxygen of the ribose ring and Q228 with the hydroxyl group at posi-
tion 200, and a hydrogen bond between E349 of the CT and the hydroxyl group at position 300
(Fig 3B). The adenine base (bound to site A) sits in a partially hydrophobic pocket. It forms
several hydrogen bonds with the side chains of T52, S53, C287 and the highly conserved N249
(93% of conservation across all sirtuin members in all species [18]), and with K250 and C287
backbone atoms (Fig 3C). E251, conserved between SIRT1, SIRT2, SIRT5, Sir2-Af2 from A. ful-
gidus and yeast Hst2 (a protein homolog to SIRT2 with sequence identity of 42%), makes
Fig 3. The NAD+ binding site in full-length SIRT2. (A)Overview of the SIRT2/NAD+ complex. The NAD+
(yellow) and catalytic residue H150 (green) are represented by sticks. The CT is highlighted in pink. The sites
A, B and C of SIRT2, which are involved in NAD+ binding, are indicated by blue circles. (B) Close-up view of
the binding site of nicotinamide and nicotinamide ribose. (C) Close-up view of the binding site of adenine.
Hydrogen bonds are highlighted by dashed lines. (D) Superposition of two crystal structures of Sir2-Af2/
NAD+ (PDB ID: 1S7G [16]) with the SIRT2/NAD+ complex (in green). The chain A (NAD+ in non-productive
conformation) and chain B (NAD+ in productive conformation) of 1S7G are colored in blue and salmon,
respectively. The NAD+ cofactors are represented by sticks.
doi:10.1371/journal.pone.0139095.g003
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hydrogen bonds with both OH groups of the adenine ribose, and is salt bridged with K350 of
the CT. The oxygen atoms of the phosphate groups that connect the two ribose groups make
several hydrogen bonds with Q130, S226 and Q228 (Fig 3C).
The CT region. The CT in both our predicted wild-type full-length models, i.e. with or
without NAD+ (Fig 1C), contains a short helix (CTH hereafter, residues T345-K350) and a lon-
ger disordered loop (CTL hereafter, residues G320-R344) connecting the CTH with the CC
(Fig 4A). CTL adapts a turn conformation around the L4-α3 of the CC, making extensive inter-
actions with the cofactor binding loop and the α9 of the zinc-binding domain (Fig 4A). CTH
binds at the edge of the nicotinamide ribose-binding site (site B) between the large Rossmann
fold and the hydrophobic pocket in the small domain (Fig 4A) in both SIRT2 and SIRT2/
NAD+. However, CTH is locked deeper into the active site of SIRT2 than SIRT2/NAD+,
because T346 in CTH occupies the binding site of the hydroxyl groups of NAD+ nicotinamide
ribose (Fig 4B). In particular, the Cα distances between T346 and H150, Q130, and V229 of the
CC decrease about 2 Å (Table 4) in SIRT2 with respect to SIRT2/NAD+. Furthermore CTH
Fig 4. Interaction of the CT region with the NAD+ binding site. (A) Detailed view of the interactions
between the CC and the CT in the SIRT2 model. The CC, NT, CTL and CTH are colored in green, blue,
yellow and pink, respectively. CTL and CTH refer to the C-terminal loop and the C-terminal α-helix,
respectively, of the CT. The hydrogen bonds are represented by dashed lines. The details of the labeled
hydrogen bonds and salt bridges are shown in Table 3. (B) Superposition of the most representative
configurations of SIRT2/NAD+ (cyan) and SIRT2 (green). The CT of SIRT2 model is colored in pink. The
NAD+ cofactor in the SIRT2/NAD+ is represented by yellow sticks. See Table 4 for the definition of the
measured atomic distances (d1, d2, d3 and d4). The two arrows from T346 and E349 refer to the two
positions of these amino acids in the SIRT2 and the SIRT2/NAD+ models. (C) Superposition of the most
representative configuration of SIRT2 (green) with the crystal structure of yeast Hst2 [79] (gray). The CT
regions of SIRT2 and Hst2 are colored in red and salmon, respectively.
doi:10.1371/journal.pone.0139095.g004
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residue E349 forms a salt bridge with R60 in the cofactor-binding loop. This stabilizes the inter-
action of the CTH with the active center in the absence of NAD+. Therefore, the SIRT2 CT
may function as an autoinhibitory region to regulate the deacetylation activity by partially
occluding the binding site of NAD+, and therefore decreasing its binding affinity for NAD+.
In SIRT2/NAD+ the E349 of the CT forms hydrogen bond interactions with the nicotinamide
ribose. This may increase the energy barrier of NAD+ for passing from the non-productive to the
active productive state, which is unfavorable for trigging the following deacetylation reaction.
We tested the hypothesis that the CT of SIRT2 has an autoinhibitory function by measuring
the catalytic activity of full-length SIRT2 and of SIRT2 with a deletion of the CT using GST
fusion proteins. We incubated GST-SIRT2, C-terminally truncated GST-SIRT2-ΔCT, or GST
alone for control with commercially available purified tubulin in the presence of NAD+. In time
course experiments we observed that SIRT2-ΔCT was more efficient in deacetylating tubulin at
K40 compared to the wild-type protein (Fig 5A and 5B) and in deacetylating a SIRT2 selective
fluorogenic substrate peptide (Fig 5C). A catalytically inactive mutant of SIRT2,
Table 3. Hydrogen bond and salt bridge interactions between the CC and the CT in SIRT2.
Interaction ID Residue a Residue b Distance (Å) c
h1 A321 K173 3.0 (0.3)
h2 N325 K99 2.9 (0.3)
h3 N325 Q105 3.0 (0.2)
h4 N325 E100 3.6 (0.9)
h5 P326 K99 2.9 (0.2)
h6 S331 D68 3.8 (1.0)
h7 S331 E71 4.4 (1.9)
h8 A339 D58 3.0 (0.2)
h9 D341 S61 3.1 (0.3)
h10 D341 S63 3.4 (0.7)
h11 T345 R60 3.6 (1.0)
h12 Q352 Q230 3.3 (0.8)
s1 K333 D68 3.5 (1.1)
s2 E349 R60 3.9 (1.9)
s3 K350 E251 4.5 (1.4)
Standard deviations are given in parentheses.
a Residues belong to the CT.
b Residues belong to the CC.
c Atomic distances (h1–h12) between donor and acceptor, and center-of-mass distances (s1–s3) between negative and positive side chains are
calculated on the equilibrium trajectory from MD simulations of SIRT2.
doi:10.1371/journal.pone.0139095.t003
Table 4. Average atomic distances (in Å) between Cα of T346 and that of H150, Q130 and Q229, and between Cς of R60 and C of E349.
Atomic distances SIRT2/NAD+ SIRT2 SIRT2-pS331
d1 Cα of H150—Cα of T346 15.5 (1.9) 13.5 (0.8) 12.3 (0.9)
d2 Cα of Q130—Cα of T346 14.2 (1.8) 12.1 (0.8) 11.0 (1.1)
d3 Cα of V229—Cα of T346 11.9 (1.0) 8.6 (0.9) 6.6 (0.8)
d4 Cς of R60—Cδ of E349 7.1 (2.3) 4.5 (1.5) 13.4 (4.6)
Standard deviations are given in parentheses.
doi:10.1371/journal.pone.0139095.t004
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GST-SIRT2-H150Y, did not show activity towards the peptide (Fig 5C). These findings are con-
sistent with the postulated activity of the CT in partially occupying the NAD+ binding pocket.
An autoinhibitory role of CT domains has also been observed in vitro for other sirtuins, i.e.
SIRT3 [85] (a member of the same sirtuin sub-class as SIRT2 [18]) and Hst2 [79]. In the latter
the CT (which is much longer, i.e. 62 amino acids instead of 33 in SIRT2, see Fig 1A)
completely occludes the active site [79] (Fig 4C). Thus our models suggest that modifications
of the CT (e.g. by phosphorylation and acetylation) might affect sirtuin deacetylase activities by
changing the location and folding of CTH and thereby regulating the loading and positioning
of NAD+ in the active center. Therefore we suggest that alterations in the flexibility of the CT
or part of the CT due to post-translational modifications may modify its autoinhibitory activity
by either enhancing or diminishing the interaction of the CT with the NAD+ binding pocket.
In turn this might then affect the binding or the positioning of the NAD+, which are important
determinants of catalytic activity.
SIRT2-pS331
Our previous study has provided evidence that S331 phosphorylation interferes with the cata-
lytic activity of SIRT2 both in vitro and in cells [15]. As S331 is located in the CT, our findings
are consistent with the suggestion that the CT affects the deacetylation activity and that this is
modulated by phosphorylation. To evaluate the hypothesis that phosphorylation of the CT at
S331 interferes with SIRT2 function by altering the interaction of the CT with the CC, we
Fig 5. Tubulin deacetylation assay with SIRT2. (A)GST-SIRT2 wild-type (wt) or a C-terminally truncated
GST-SIRT2-ΔCT fusion proteins were incubated with commercially available purified tubulin in the presence
of NAD+ for the indicated periods of time (0 to 90 minutes). GST was included as a negative control. The
samples were subjected to SDS-PAGE and either stained by Coomassie blue (CB) or tubulin and acetylated
tubulin were measured byWestern blot analysis using specific antibodies (IB). (B)Quantification of three
independent experiments. Mean values and standard deviations are indicated. (C)GST-SIRT2 wild-type,
catalytically inactive GST-SIRT2-H150Y or GST-SIRT2-ΔCT fusion proteins were assayed using a
fluorometric SIRT2 substrate. Three independent experiments were quantified, mean values and standard
deviations are indicated. The insert shows the GST fusion proteins used in the assays. Statistical significance
was evaluated using a two-sided students T-test: * p<0.05, ** p<0.01.
doi:10.1371/journal.pone.0139095.g005
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modeled SIRT2 with phosphorylation at S331 (SIRT2-pS331). The good sampling and conver-
gence of the 500 ns long MD simulations on SIRT2-pS331 were confirmed by the PC analysis,
i.e. the cosine contents for the first three PCs are 0.320, 0.231, and 0.369. While the CC domain
does not change significantly (backbone RMSD values are 2.4±0.2 Å with respect to the X-ray
structure [13], see S2B Fig), the CT shows large conformational changes with its average back-
bone RMSD (S2B Fig) during the simulations being 4.9±0.7 Å (Fig 6). Due to the repulsion
between pS331 and E71 and D68 in the cofactor binding loop, the backbone of the phosphory-
lated CT moves ~10.7 Å away from the CC. pS331 forms a salt bridge with K333, and D68 salt
bridges with K334. As a result, the CTH becomes fully unfolded and the autoinhibitory region
moves deeper into the NAD+ binding pocket by ~1.5 Å compared to the unphosphorylated
SIRT2 (Table 4 and S3 Fig). This new configuration of the CTH is stabilized by two salt bridges
formed between R344 in the CT and D58 in the CC, and between R348 in the CT and D257 in
the CC. T346 occupies the presumed binding site of nicotinamide ribose (Fig 6). The results of
our simulations support the hypothesis that phosphorylation of the CT at amino acid S331
induces a conformational change that contributes to the regulation of the autoinhibitory region
of the CT. These findings are consistent with the previous biochemical findings that phosphor-
ylation of S331 inhibits SIRT2 catalytic activity [15]. In broader terms other modifications of
the CT may also affect the interaction of the CT with the NAD+ binding site and thus regulate
catalytic activity of SIRT2.
Conclusions
In summary, we present full-length molecular models of apo-SIRT2, the SIRT2/NAD+ com-
plex and SIRT2-pS331 by using bioinformatics tools and MD simulations. Based on the models
Fig 6. Interaction of the S331 phosphorylated CT region with the NAD+ binding site. Superposition of
the most representative configurations of SIRT2 (cyan) and SIRT2-pS331 (green). The CT of SIRT2-pS331 is
colored in pink. The NAD+ cofactor in the SIRT2/NAD+ is represented by yellow sticks.
doi:10.1371/journal.pone.0139095.g006
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and the functional analysis of the CT and of the phosphorylation at S331, we suggest that the
C-terminal region of SIRT2 functions as an autoinhibitory region that regulates the deacetyla-
tion activity of SIRT2. This can occur by increasing the stability of the non-productive NAD+
in SIRT2/NAD+ and/or partially occupying the NAD+ binding site in apo-SIRT2. The inhibi-
tory role of the CT region is consistent with the increased catalytic activity of a SIRT2 mutant
that lacks this region. Phosphorylation at S331 causes large conformational changes in the CT
that enhance the autoinhibitory activity of the CT region. This is consistent with our previous
findings that CDK-dependent modification of S331 inhibits SIRT2 catalytic activity both in
vitro and in cells [15]. Together these findings suggest that the CT region of SIRT2 might func-
tion more generally in integrating signals that target and regulate this deacetylase during cellu-
lar processes. Moreover the molecular insight into the role of the CT region in controlling
SIRT2 function provided by our work might help to design specific inhibitors to control SIRT2
deacetylation activity for therapeutic applications.
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